1,077 Shares in Insulet Co. (NASDAQ:PODD) Purchased by Gray Wealth Management Inc.

Gray Wealth Management Inc. acquired a new stake in shares of Insulet Co. (NASDAQ:PODD) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,077 shares of the medical instruments supplier’s stock, valued at approximately $234,000.

A number of other hedge funds have also recently bought and sold shares of the business. Qube Research & Technologies Ltd boosted its stake in shares of Insulet by 227.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier’s stock valued at $61,673,000 after buying an additional 268,553 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Insulet by 119.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 79,375 shares of the medical instruments supplier’s stock valued at $17,223,000 after acquiring an additional 43,147 shares during the last quarter. Asset Management One Co. Ltd. boosted its stake in Insulet by 33.7% during the 4th quarter. Asset Management One Co. Ltd. now owns 36,677 shares of the medical instruments supplier’s stock valued at $8,048,000 after acquiring an additional 9,240 shares during the last quarter. Graham Capital Management L.P. grew its holdings in Insulet by 689.8% during the 3rd quarter. Graham Capital Management L.P. now owns 23,095 shares of the medical instruments supplier’s stock worth $3,683,000 after acquiring an additional 20,171 shares in the last quarter. Finally, Aquila Investment Management LLC bought a new stake in shares of Insulet in the 4th quarter worth about $1,302,000.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. increased their price target on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Robert W. Baird raised Insulet from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $180.00 to $238.00 in a report on Thursday, December 21st. Barclays lowered their price target on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. Stifel Nicolaus raised their price objective on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research note on Monday, February 5th. Finally, Piper Sandler lowered their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $243.21.

Insider Buying and Selling at Insulet

In other news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the transaction, the director now owns 2,567 shares of the company’s stock, valued at $418,215.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.90% of the stock is owned by company insiders.

Insulet Stock Performance

Shares of PODD stock traded down $1.53 during trading hours on Thursday, reaching $164.73. The stock had a trading volume of 589,071 shares, compared to its average volume of 874,858. The firm has a market capitalization of $11.53 billion, a PE ratio of 57.13, a price-to-earnings-growth ratio of 3.11 and a beta of 0.98. The firm has a 50-day simple moving average of $175.14 and a 200-day simple moving average of $178.90. Insulet Co. has a twelve month low of $125.82 and a twelve month high of $335.91. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating the consensus estimate of $0.67 by $0.73. The company had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. Insulet’s revenue was up 37.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.55 earnings per share. As a group, equities analysts forecast that Insulet Co. will post 3.08 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.